(PJF) to be radiographic evidence of PJK plus clinical sequelae that require revision surgery, including pain, neurological deficit, and impaired quality of life. 9, 23 The causes of PJK/PJF are multifactorial and include age-related degeneration, poor bone quality, ligamentous fatigue, vertebral body fractures, instrumentation failure, and degenerative disc disease. 1, 2, 8, 23, 26 Additional surgical risk factors include older age at the time of surgery, 3, 13, 15, 25 preoperative sagittal imbalance, 16, 17, 19, 20, [30] [31] [32] increased curvature correction, 16, 17, 30 and disruption of the facets and posterior ligamentous complex. 3, 13, 17, 20 Rates of PJK vary by report and definition, but generally range from around 20% to 40%. 8, 14, 15, 24, 31, 32 Most cases occur relatively early in the postoperative period, with 66% of cases observed in the first 3 months and 80% within the first 18 months. 30, 32 Given the morbidity and cost associated with PJK/ PJF, particularly surgical revision, PJK prevention strategies are increasingly important. Surgical adjuncts, such as vertebroplasty, ligament augmentation, hook fixation at the UIV, and careful rod contouring, have been used with varying success. These adjuncts often go unreimbursed by insurance companies, despite their potential for significant cost savings. In this study, we sought to determine the efficacy of surgical adjuncts for PJK and model the costeffectiveness in a large population of patients with adult spinal deformity.
Methods

Data Collection
A series of 200 adult spinal deformity patients undergoing instrumented fusion were included in this study. Surgeries were performed from 2010 to 2017 at a single institution by 2 surgeons (V.D. and C.P.A). Patient demographics and surgical characteristics, including age, sex, indication for surgery, number of levels fused, use of bone morphogenetic protein (BMP), vertebroplasty (Cortoss cement, Stryker), hook fixation at the UIV (for constructs terminating in the upper thoracic spine), ligament augmentation (LigaPASS cable, Medicrea), 3-column osteotomy, and pelvic fixation, were collected.
Vertebroplasty, performed by tapping the cannulated pedicle screw trajectories and filling them with thrombincontaining hemostatic matrix to occlude venous channels, was done at the UIV and UIV+1 in a subset of lower-thoracic constructs. Cement was then injected into the vertebral bodies with a volume of 3 ml at each entry site (6 ml per vertebral body). Ligament augmentation was performed in a subset of patients throughout the thoracic and lumbar spine at the UIV-1, UIV, and UIV+1 levels. This technique involves using a matchstick burr to drill through the center of the spinous processes at these levels and then passing a soft sublaminar cable through these holes in a mirrored fashion. The cable was pulled tight on each side by hand to allow testing of the exact tension desired and then fixed to the rod using supplied connectors. Spinous processes at these levels are loaded in slight extension to resist flexion at the terminal construct. Patients with neuromuscular or neurodegenerative disorders were excluded from analysis, and only patients with at least 6 months of follow-up were included. Only patients with data on total and direct cost of index and revision surgeries were included. PJF was defined as PJK of greater than 10° plus clinical sequelae requiring revision surgery. Upper thoracic levels were defined as T1-6, and lower thoracic levels were defined as T7-12. All activities were approved by the Committee on Human Research, our institutional review board.
Statistical Analysis
Univariate analysis was performed using the chi-square test for categorical variables and the t-test for continuous variables. Binary logistic regression was used to generate a multivariate model that included all variables that were significant on univariate analysis plus those variables with known associations with PJF. Sensitivity analyses were performed by independently varying the cost of ligament augmentation, rate of PJF prevention, and cost of reoperation to determine if the intervention remained cost-effective under each of those scenarios. Statistical significance was defined as p < 0.05.
Cost Analysis
Total and direct hospital costs for each hospitalization were obtained from the hospital's accounting database and are reported in US dollars. Total costs include direct costs (e.g., imaging, medications, surgical supplies, hospital room) and indirect costs (such as administrative, facilities, and overhead fees not directly attributable to an individual patient). Of note, physician payments and noninstitutional costs incurred in the care of these patients (e.g., inpatient rehabilitation stay after discharge, outpatient physical therapy) are not available in our database and therefore not included in our calculations.
Cost-benefit analyses were performed by calculating the direct cost required for ligament augmentation in the index surgery versus the prevention of the cost of reoperation surgery. Sensitivity analyses were performed by independently varying the cost of ligament augmentation, rate of PJF prevention, and cost of reoperation by ± 50% to determine if the intervention remained cost-effective under each of those scenarios.
Results
Patient Demographics
A total of 200 patients were identified; 5 were excluded due to lack of cost data, leaving 195 patients in our final analysis. The mean age was 64 years (range 25-84 years), and 135 patients (69%) were women. The mean number of levels fused was 10 (range 2-18). The UIV was cervical in 2 cases (1%), upper thoracic in 73 cases (37%), lower thoracic in 108 cases (55%), and lumbar in 12 cases (6%). Three-column osteotomies were used in 82 patients (42%). Pelvic fixation was used in 190 cases (97%). Surgical adjuncts were also quantified: ligament augmentation was used in 99 cases (51%), hook fixation at the UIV in 60 cases (31%), vertebroplasty in 71 cases (36%), BMP in 133 cases (68%), and 4-rod constructs with 3-column osteotomies in 78 cases (40%). PJF occurred in 18 cases (9%). The mean total cost of index surgery was $129,953 ± $32,177 ($80,368 ± $19,882 in direct cost). The mean cost of the revision surgery was $193,277 ± $152,613 ($119,217 ± $94,212 in direct cost). The mean length of follow-up was 22 months (range 6-78 months). These data are summarized in Table 1 .
Statistical Analysis of PJF Rates
The effect of individual PJF prevention techniques was first assessed by univariate analysis. Ligament augmentation was associated with a 4% rate of PJF (4 of 99), compared with 15% (14 of 96) in patients without ligament augmentation (p = 0.011). Hook fixation at the UIV was associated with a PJF rate of 2% (1 of 60), compared with 13% (17 of 135) in those without (p = 0.014). Neither vertebroplasty nor BMP was associated with reduced rates of PJF (p = 0.819 and p = 0.498, respectively). These data are summarized in Table 2 .
Since hook fixation is only used in upper thoracic constructs and vertebroplasty in lower thoracic constructs, we generated a multivariate model to control for other important confounders, including age, sex, and UIV, since hook fixation is only used in upper thoracic levels. In this multivariate model, only ligament augmentation was significantly associated with a reduction in PJF (OR 0.196, 95% CI 0.050-0.774; p = 0.020). Age, sex, UIV, and hook fixation were not associated with a reduction in PJF. Results of multivariate analysis are summarized in Table 3 . Given the role of ligament augmentation in PJF prevention, we compared demographics, surgical characteristics, and both total and direct costs between patients who received ligament augmentation and those who did not. Age was significantly older in the ligament augmentation group (66 vs 63 years, p = 0.025), as were the number of levels fused (11 vs 10 levels, p = 0.043). The UIV did not significantly differ with respect to upper and lower thoracic constructs; however, there were more lumbar UIVs in the group without ligament augmentation (11% vs 1%, p = 0.002). We compared the UIV in patients with and without ligament augmentation who developed PJF. In the group with ligament augmentation, 4 patients developed PJF. The UIV levels in these patients were as follows: 1 at C-7 and 3 at T-10. In the group without ligament augmentation, the UIV levels were as follows: 3 each at T-10 and T-12, 2 each at T-11 and L-1, and 1 each at T-3, T-4, T-9, and L-2.
Rates of PJF were lower in the ligament augmentation group (4% vs 15%, p = 0.011), but the mean follow-up was also shorter in the ligament augmentation group (16 vs 29 months, p < 0.001). The cost of index surgery was significantly higher for patients with ligament augmentation, and the cost of revision surgery for patients with ligament augmentation was notably lower; however, the difference did not reach statistical significance. These data are summarized in Table 4 . 
Cost-Benefit Analysis
We then performed a cost-benefit analysis for ligament augmentation in the prevention of PJF. Specifically, we compared the cost of ligament augmentation in the index case ($1100) versus the cost of reoperation for PJF ($119,217). Since ligament augmentation produced a 10.5% reduction in the rate of PJF in our patient cohort, we calculated that 9.5 patients had to receive ligament augmentation in their index surgery in order to prevent 1 reoperation for PJF (this is the number needed to treat [NNT] ). This means that we spent $10,450 for ligament augmentation upfront in 9.5 patients in order to prevent a $119,217 revision surgery in 1 patient. Scaled to a theoretical cohort of 100 patients receiving ligament augmentation, the estimated savings would be $1,144,916.
To assess the robustness and generalizability of our results, we performed sensitivity analyses for the cost-benefit of ligament augmentation for PJF prevention. The value of each parameter (PJF reduction rate, cost of ligament augmentation, and cost of reoperation) was independently varied by ± 50%. At baseline, $108,767 was saved by using ligament augmentation upfront to prevent reoperation for PJF. The use of ligament augmentation remained cost-effective, with savings per 100 patients ranging from $515,889 to $1,772,374, in all variations. These data are summarized in Table 5 .
Given that different hospitals have various implant prices, we performed a continuous sensitivity analysis for ligament augmentation implant price (Fig. 1) . The threshold price under which ligament augmentation remained cost-effective in preventing PJF was $12,549, which is a significant increase from the price currently negotiated at our center ($1100) and more than the cost difference between patients with and without ligament augmentation ($11,035).
Discussion
Prevention strategies for PJK/PJF are of increasing importance in adult spinal deformity. In addition to the significant morbidity and clinical impact on patients, the cost of revision surgery carries a significant economic impact. 18 Reducing rates of PJF therefore has the potential to produce significant cost savings. 29 Several techniques believed to reduce the risk of PJK/PJF include extending fusion constructs to include levels with baseline segmental kyphosis of more than 5°, using composite metals with greater flexibility, minimizing the destruction of soft tissue at the UIV, achieving optimal spinal balance postoperatively, and using transition rods. 2, 4, 5, 8, 19, 20 The use of hook fixation at the UIV, as shown in our data, is also associated with decreased rates of PJK/PJF. This technique provides a theoretical advantage since the hooks require less violation of the facet joint and provide more dynamic fixation at the top of the construct. 10, 12, 16 Several studies have compared PJK rates in patients with spinal hooks to those with pedicle screws at the UIV; rates of PJK in those with hooks ranged from 0% to 30%, compared with 30% to 35% in those with pedicle screw constructs. 10, 16 Our clinical practice has evolved over the past 5 years, with PJF prevention becoming a significant priority for all deformity cases. 28 Since the proposed mechanism of PJK in the upper thoracic spine is ligamentous fatigue, we use hook fixation at the UIV for all constructs terminating at those levels. We also introduce terminal kyphosis into the rod so it is never forced into place, which prevents additional loading forces to the construct and minimizes the risk for screw pullout or junctional stress. For constructs terminating in the lower thoracic spine, we perform vertebroplasty at the UIV and UIV-1 levels since failures at the thoracolumbar spine are often due to fractures. We use ligament augmentation in all cases, as it is an emerging strategy for PJF prevention. The goal of this technique is to reinforce the junction between the UIV and adjacent noninstrumented vertebrae while minimizing facet joint violation. 27 Our data indicate that this strategy is highly effective in reducing the rate of PJF after surgery for adult spinal deformity, producing a 10.5% reduction in PJF in patients with ligament augmentation compared with those without ligament augmentation.
Prior studies have demonstrated that readmissions and reoperations in patients with adult spinal deformity are associated with a significant increase in costs and reduction in the cost-effectiveness of deformity correction. 6, 22, 29 Reoperations for PJF often require large surgeries with extension of instrumentation, making PJF a particularly costly complication. In this context, our analysis suggests that the use of ligament augmentation is highly cost-effective. Implant costs associated with ligament augmentation total approximately $1100, or 1.4% of the direct cost of the primary surgery. Given the NNT of 9.5, the cost of preventing 1 reoperation is $10,450, which is $108,767 less than the mean cost of a reoperation for PJF. The potential cost savings are thus substantial. Recent estimates suggest that rates of patients undergoing fusion for adult spinal deformity are increasing, with 6728 cases in 2013 at a rate 
FIG. 1.
Sensitivity analysis of ligament augmentation price. When varying the price of ligament augmentation, the intervention remains cost-effective as long as the price is less than $12,549. The current negotiated price at our center is $1100. of 13.9 per 100,000 adults per year in the United States. 33 Based on an NNT of 9.5, ligament augmentation has the potential to prevent 10.5 reoperations per 100 patients with a savings of over $1.25 million. When scaled to 6728 cases annually, this results in a savings of over $84 million per year. Although not all of these cases are large deformity corrections that are generalizable to the population included in this study, even a conservative estimate using one-third of all deformity corrections (approximately 2241 patients per year), would result in a savings of over $28 million annually by using ligament augmentation in primary index surgeries for deformity. Direct costs associated with the primary surgery, ligament augmentation, and reoperation for PJF are likely to vary by center based on negotiated prices with implant manufacturers and other determinants of surgical cost, including patient factors, surgeon preferences, hospital practices, and regional variability. 6, 7, 11, 21, 22 Along similar lines, a relative paucity of data exists regarding the reduction in PJF produced by ligament augmentation, 27 and it is possible that the reduction in PJF achieved with ligament augmentation may vary as this technique is adopted at other centers. Our sensitivity analysis indicates that even if ligament augmentation produced half the reduction in PJF we observed at our institution, it would still be highly cost-effective in these settings.
There are certain limitations to the present study that are inherent to its retrospective design, such as selection bias and moderate sample size. Although this was a cohort of purely adult spinal deformity patients, they were not randomized to PJF prevention strategy or surgical plan. The retrospective design also limits the ability to control for confounding variables such as bone mineral density scores or other clinical factors that can contribute to increased risk of PJF. This study design also limits our ability to capture postoperative events, including revision surgery, since patients were not included in a prospective cohort where adverse events or revision surgeries are more completely captured. These cohorts have some inherent heterogeneity since ligament augmentation is a more recent technique. Our practice pattern has evolved in a fluid manner, so that patients who underwent ligament augmentation were also more likely to have hook fixation (for constructs terminating in the upper thoracic spine), vertebroplasty (for constructs terminating in the lower thoracic spine or thoracolumbar junction), BMP, and gentle contouring of the rods, which could not be retrospectively assessed. The use of these additional surgical adjuncts helps explain the nearly $10,000 difference in the direct cost of primary surgery in the ligament augmentation group compared with the group without ligament augmentation, since the price of ligament augmentation alone is only $1100. We utilized a multivariate model to help control for these differences, but future studies should utilize an entirely contemporary cohort across multiple centers to determine the reproducibility of these data. In addition, it is important to note that our cost data do not include outpatient costs, such as physical therapy or rehabilitation. We would expect that PJF reoperation costs also including outpatient costs would be even higher than those calculated here, making ligament augmentation even more cost-effective for these patients.
Conclusions
Ligament augmentation is a novel strategy for PJK/PJF prevention. Even when controlling for age, sex, UIV, and use of other surgical adjuncts, ligament augmentation continues to demonstrate a significant reduction in PJF and the need for revision surgery. Using sensitivity analysis, we showed that even dramatic variations in the reduction of PJF rates, cost of ligament augmentation, and cost of reoperation do not change the significant cost-effectiveness of this treatment. Future studies will need to determine if these data are reproducible in large cohorts of adult spinal deformity patients and control for other important confounders including bone mineral density. However, given the current cost of ligament augmentation and relative ease of implementing this strategy in the operating room, this technique warrants consideration for all adult spinal deformity cases, particularly for patients at high risk for PJK/ PJF.
